Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells

Cytokine

Volumn 59, Issue 2, 2012, Pages 423-432

  Chiu, Hsiao Ying ^a   Sun, Kuang Hui ^b   Chen, Shiow Yi ^a   Wang, Hsiao Hsien ^c   Lee, Ming Yung ^d   Tsou, Yu Chi ^a   Jwo, Shyh Chuan ^e   Sun, Guang Huan ^d   Tang, Shye Jye ^a  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Cell migration; MCP 1 CCL2; Paxillin; PKC

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; PAXILLIN; PROTEIN KINASE C; SHORT HAIRPIN RNA; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CCL2; ENZYME ACTIVATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; NEOPLASM INVASIVENESS; PAXILLIN; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN KINASE C; RECEPTORS, CCR2; URINARY BLADDER NEOPLASMS;

MUS;

EID: 84862313021     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.04.017     Document Type: Article

References (52)

1. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-326.
2. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
3. Insel P.A., Tang C.M., Hahntow I., Michel M.C. Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta 2007, 1768:994-1005.
4. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
5. Loberg R.D., Day L.L., Harwood J., Ying C., St John L.N., Giles R., et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006, 8:578-586.
6. Nam J.S., Kang M.J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., et al. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 2006, 66:7176-7184.
7. Li X., Loberg R., Liao J.H., Ying C., Snyder L.A., Pienta K.J., et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009, 69:1685-1692.
8. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
9. Vazquez-Lavista L.G., Lima G., Gabilondo F., Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 2009, 74:414-418.
10. Attar R., Agachan B., Kuran S.B., Cacina C., Sozen S., Yurdum L.M., et al. Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo 2010, 24:243-248.
11. Selam B., Kayisli U.A., Akbas G.E., Basar M., Arici A. Regulation of FAS ligand expression by chemokine ligand 2 in human endometrial cells. Biol Reprod 2006, 75:203-209.
12. Luo Y., Chen X., O'Donnell M.A. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007, 147:370-378.
13. van Golen K.L., Ying C., Sequeira L., Dubyk C.W., Reisenberger T., Chinnaiyan A.M., et al. CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. J Cell Biochem 2008, 104:1587-1597.
14. Lu Y., Cai Z., Galson D.L., Xiao G.Z., Liu Y.L., George D.E., et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006, 66:1311-1318.
15. Lu Y., Chen Q.Y., Corey E., Xie W., Fan J., Mizokami A., et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009, 26:161-169.
16. Sharma S., Ksheersagar P., Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician 2009, 80:717-723.
17. Merseburger A.S., Matuschek I., Kuczyk M.A. Bladder preserving strategies for muscle-invasive bladder cancer. Curr Opin Urol 2008, 18:513-518.
18. Amann B., Perabo F.G., Wirger A., Hugenschmidt H., Schultze-Seemann W. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol 1998, 82:118-121.
19. Narter K.F., Agachan B., Sozen S., Cincin Z.B., Isbir T. CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res 2010, 9:685-692.
20. Cotton M., Claing A. G protein-coupled receptors stimulation and the control of cell migration. Cell Signal 2009, 21:1045-1053.
21. Tumbarello D.A., Brown M.C., Hetey S.E., Turner C.E. Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin delta. J Cell Sci 2005, 118:4849-4863.
22. Downey C., Craig D.H., Basson M.D. Pressure activates colon cancer cell adhesion via paxillin phosphorylation, Crk, Cas, and Rac1. Cell Mol Life Sci 2008, 65:1446-1457.
23. Eisenhardt A., Frey U., Tack M., Rosskopf D., Lummen G., Rubben H., et al. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol 2005, 47:111-117.
24. Retz M.M., Sidhu S.S., Blaveri E., Kerr S.C., Dolganov G.M., Lehmann J., et al. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 2005, 114:182-189.
25. Kawanishi H., Matsui Y., Ito M., Watanabe J., Takahashi T., Nishizawa K., et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008, 14:2579-2587.
26. Metalli D., Lovat F., Tripodi F., Genua M., Xu S.Q., Spinelli M., et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010, 176:2997-3006.
27. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 47:222-225.
28. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267:271-285.
29. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
30. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
31. Esrig D., Spruck C.H., Nichols P.W., Chaiwun B., Steven K., Groshen S., et al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993, 143:1389-1397.
32. Chai C.Y., Huang Y.C., Hung W.C., Kang W.Y., Chen W.T. Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells. Mutagenesis 2007, 22:403-408.
33. Fechner G., Perabo F.G., Schmidt D.H., Haase L., Ludwig E., Schueller H., et al. Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. Urology 2003, 61:468-473.
34. Konstantakou E.G., Voutsinas G.E., Karkoulis P.K., Aravantinos G., Margaritis L.H., Stravopodis D.J. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 2009, 35:401-416.
35. Chang F.L., Ling Y.F., Lai M.D. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Anticancer Res 2000, 20:329-336.
36. Pagliaro L.C., Keyhani A., Liu B., Perrotte P., Wilson D., Dinney C.P. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003, 21:456-462.
37. Wada Y., Gotoh A., Shirakawa T., Hamada K., Kamidono S. Gene therapy for bladder cancer using adenoviral vector. Mol Urol 2001, 5:47-52.
38. Hacke K., Rincon-Orozco B., Buchwalter G., Siehler S.Y., Wasylyk B., Wiesmuller L., et al. Regulation of MCP-1 chemokine transcription by p53. Mol Cancer 2010, 9:82-93.
39. Cheng J.C., Auersperg N., Leung P.C. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Oncogene 2011, 30:1020-1031.
40. Muller P.A., Vousden K.H., Norman J.C. P53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011, 192:209-218.
41. Schwock J., Dhani N., Hedley D.W. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010, 14:77-94.
42. Brown M.C., Turner C.E. Paxillin: adapting to change. Physiol Rev 2004, 84:1315-1339.
43. Goel H.L., Dey C.S. PKC-regulated myogenesis is associated with increased tyrosine phosphorylation of FAK, Cas, and paxillin, formation of Cas-CRK complex, and JNK activation. Differentiation 2002, 70:257-271.
44. Yu J.A., Deakin N.O., Turner C.E. Paxillin-kinase-linker tyrosine phosphorylation regulates directional cell migration. Mol Biol Cell 2009, 20:4706-4719.
45. Liao W.X., Feng L., Zheng J., Chen D.B. Deciphering mechanisms controlling placental artery endothelial cell migration stimulated by vascular endothelial growth factor. Endocrinology 2010, 151:3432-3444.
46. Sen A., O'Malley K., Wang Z., Raj G.V., Defranco D.B., Hammes S.R. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010, 285:28787-28795.
47. Tapia J.A., Camello C., Jensen R.T., Garcia L.J. EGF stimulates tyrosine phosphorylation of focal adhesion kinase (p125FAK) and paxillin in rat pancreatic acini by a phospholipase C-independent process that depends on phosphatidylinositol 3-kinase, the small GTP-binding protein, p21rho, and the integrity of the actin cytoskeleton. Biochim Biophys Acta 1999, 1448:486-499.
48. Lee M.S., Kim Y.B., Lee S.Y., Kim J.G., Kim S.H., Ye S.K., et al. Integrin signaling and cell spreading mediated by phorbol 12-myristate 13-acetate treatment. J Cell Biochem 2006, 99:88-95.
49. Faoro L., Loganathan S., Westerhoff M., Modi R., Husain A.N., Tretiakova M., et al. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs 2008, 19:841-848.
50. Wang J.F., Park I.W., Groopman J.E. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood 2000, 95:2505-2513.
51. Romanova L.Y., Hashimoto S., Chay K.O., Blagosklonny M.V., Sabe H., Mushinski J.F. Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive. J Cell Sci 2004, 117:3759-3768.
52. Li C., Wernig F., Leitges M., Hu Y., Xu Q. Mechanical stress-activated PKCdelta regulates smooth muscle cell migration. FASEB J 2003, 17:2106-2108.